AI Site Selection Sounds Fast — Until You See What Happens After the Algorithm Picks Your Site
ASCO and Ryght AI are using algorithms to select CDK4/6 inhibitor trial sites. Here's what ops teams need to...
When AI Picks Your Site, Execution Still Happens in the Building
ASCO and Ryght AI are using machine learning to select breast cancer trial sites. Here's what that means for...
When Your CRO’s Books Were Wrong, Your Trial Budget Probably Was Too
ICON's $158M revenue restatement across 2023–2024 exposes how CRO accounting gaps cascade into site payment delays, contract disputes, and...
Your CTMS Wasn’t Built for Neural Data — Kordata’s Launch Proves It
Kordata Dynamics launches an AI model built for real-time neural data in trials. Here's what it means for site...
The Coordinator Crunch Is Costing You Patients — Not Just Morale
Coordinator burnout drives enrollment collapse. Here's the operational math sponsors miss—and what sites need from Monday morning.
When Bad Protocol Design Hits Your Site, AI Won’t Save You
Phesi finds fewer than 1 in 3 trial protocols connect to real patient data — meaning flawed assumptions reach...
When AI Scales Your Protocol, It Scales Every Flaw Inside It
Phesi's 2026 analysis found fewer than 1 in 3 trial protocols are linked to patient data—meaning AI tools are...
Mid-Trial Site Additions Sound Like Progress — The Activation Math Tells a Different Story
NKGen Biotech just added 3 Alzheimer's trial sites across NJ, NY, and FL. Here's what the activation math actually...
The eCOA Vendor Stack You Built Is Already Obsolete
Signant Health's acquisition of Ametris on May 14 consolidates eCOA and wearable data streams—and exposes the real cost of...
ICON’s San Antonio Expansion Looks Like Opportunity—Your IRB Timeline Says Otherwise
ICON opens early-phase units in San Antonio, Houston, and Lawrence, KS—but sponsors activating satellite clinics face IRB, contract, and...